Prothena | PRTA - Operating Profit


Prothena reported $-18.69M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
ALKERMES USD -65.93M 17.65M Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amgen USD 4.61B 777M Jun/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Exelixis USD 268.42M 20.01M Sep/2026
Immunic USD -23.33M 2.67M Dec/2025
Incyte USD -707.47M 1.41B Sep/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
MacroGenics USD -13.85M 19.59M Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Prothena USD -18.69M 44.48M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026